

# Immunological biomarkers predict HIV-1 viral rebound

Nature Communications

6, 8495

DOI: [10.1038/ncomms9495](https://doi.org/10.1038/ncomms9495)

Citation Report

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 2  | Highlights from the Conference on Retroviruses and Opportunistic Infections 2016. <i>Journal of Virus Eradication</i> , 2016, 2, 124-130.  | 0.3  | 0         |
| 3  | Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005661.   | 2.1  | 152       |
| 4  | International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.   | 15.2 | 395       |
| 5  | Immune activation and paediatric HIV-1 disease outcome. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 146-155.  | 1.5  | 39        |
| 6  | Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 69-73.   | 0.9  | 38        |
| 7  | Immunological strategies to target HIV persistence. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 402-408.  | 1.5  | 8         |
| 8  | Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. <i>Journal of Translational Medicine</i> , 2016, 14, 44.   | 1.8  | 15        |
| 9  | Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy. <i>Aids</i> , 2016, 30, 2303-2313.   | 1.0  | 26        |
| 10 | Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. <i>Cell Host and Microbe</i> , 2016, 20, 368-380.  | 5.1  | 170       |
| 11 | Kill. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 409-416.  | 1.5  | 24        |
| 12 | Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection. <i>Medicine (United States)</i> , 2016, 95, e3738.  | 0.4  | 18        |
| 13 | Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. <i>Retrovirology</i> , 2016, 13, 21. | 0.9  | 21        |
| 14 | Post-Treatment Controllers: Role in HIV "Cure" Research. <i>Current HIV/AIDS Reports</i> , 2016, 13, 1-9.  | 1.1  | 31        |
| 15 | Curing HIV: Moving Forward Faster. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 125-128.  | 0.5  | 5         |
| 16 | Paediatric HIV infection: the potential for cure. <i>Nature Reviews Immunology</i> , 2016, 16, 259-271.  | 10.6 | 97        |
| 17 | HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection. <i>Journal of Virology</i> , 2017, 91, .   | 1.5  | 31        |
| 18 | Fluorescent silver nanoparticle based highly sensitive immunoassay for early detection of HIV infection. <i>RSC Advances</i> , 2017, 7, 19863-19877.   | 1.7  | 38        |
| 19 | Early antiretroviral therapy reduces HIV DNA following perinatal HIV infection. <i>Aids</i> , 2017, 31, 1847-1851.   | 1.0  | 26        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 20 | Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2017, 215, S134-S141.  | 1.9  | 39        |
| 21 | Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients. <i>Aids</i> , 2017, 31, 1895-1897.   | 1.0  | 16        |
| 22 | Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1471-1478.  | 2.9  | 34        |
| 23 | Barriers to HIV remission research in low- and middle-income countries. <i>Journal of the International AIDS Society</i> , 2017, 20, 21521.  | 1.2  | 16        |
| 24 | Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , 2017, 91, .   | 1.5  | 10        |
| 25 | Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. <i>Journal of Medical Ethics</i> , 2018, 44, medethics-2017-104433.   | 1.0  | 51        |
| 26 | The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy. <i>Medicine (United States)</i> , 2017, 96, e7430.   | 0.4  | 8         |
| 27 | Immune Checkpoint Inhibitors in Melanoma and HIV Infection. <i>Open AIDS Journal</i> , 2017, 11, 91-100.   | 0.1  | 12        |
| 28 | HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells. <i>Frontiers in Immunology</i> , 2017, 8, 376.   | 2.2  | 26        |
| 29 | Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection. <i>Frontiers in Immunology</i> , 2017, 8, 495.  | 2.2  | 11        |
| 30 | Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle Sanctuary. <i>Frontiers in Immunology</i> , 2017, 8, 622.   | 2.2  | 8         |
| 31 | Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. <i>Journal of Histochemistry and Cytochemistry</i> , 2018, 66, 427-446. | 1.3  | 19        |
| 32 | Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. <i>Retrovirology</i> , 2018, 15, 18.   | 0.9  | 76        |
| 33 | Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained. <i>Retrovirology</i> , 2018, 15, 22.   | 0.9  | 35        |
| 34 | Novel therapies/hopes for HIV cure in perinatally acquired HIV-positive adolescents. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 281-287.   | 1.5  | 5         |
| 35 | Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.  | 10.6 | 407       |
| 37 | Cell Size-Based Decision-Making of a Viral Gene Circuit. <i>Cell Reports</i> , 2018, 25, 3844-3857.e5.   | 2.9  | 10        |
| 38 | Targeting Immune Checkpoint Molecules to Eliminate Latent HIV. <i>Frontiers in Immunology</i> , 2018, 9, 2339.   | 2.2  | 32        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 39 | Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs?. <i>Frontiers in Immunology</i> , 2017, 8, 1966.  | 2.2  | 3         |
| 40 | CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. <i>Frontiers in Immunology</i> , 2018, 9, 928.  | 2.2  | 50        |
| 41 | CD3 $\mu$ Expression Defines Functionally Distinct Subsets of V $\hat{1}$ T Cells in Patients With Human Immunodeficiency Virus Infection. <i>Frontiers in Immunology</i> , 2018, 9, 940.  | 2.2  | 15        |
| 42 | Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2000.   | 1.8  | 33        |
| 43 | Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. <i>Aids</i> , 2018, 32, 1491-1497.  | 1.0  | 136       |
| 44 | Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. <i>Nature Medicine</i> , 2018, 24, 923-926.   | 15.2 | 263       |
| 45 | Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers. <i>PLoS Computational Biology</i> , 2019, 15, e1007229.  | 1.5  | 30        |
| 46 | Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 1112-1122.   | 0.5  | 12        |
| 47 | Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model. <i>MBio</i> , 2019, 10, .   | 1.8  | 14        |
| 48 | Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. <i>Nature Communications</i> , 2019, 10, 4109.   | 5.8  | 72        |
| 49 | The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like. <i>Frontiers in Immunology</i> , 2019, 10, 2251.   | 2.2  | 48        |
| 50 | The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2298.  | 2.2  | 244       |
| 51 | Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. <i>PLoS ONE</i> , 2019, 14, e0211112.   | 1.1  | 16        |
| 52 | Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e297-e306.                                     | 2.1  | 73        |
| 53 | Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2039-2046. | 1.3  | 28        |
| 54 | Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€”report of a consensus meeting. <i>Lancet HIV</i> , the, 2019, 6, e259-e268.   | 2.1  | 139       |
| 55 | Gold nanoparticle-carboxymethyl cellulose nanocolloids for detection of human immunodeficiency virus type-1 (HIV-1) using laser light scattering immunoassay. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 177, 377-388.                        | 2.5  | 28        |
| 56 | PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. <i>Nature Communications</i> , 2019, 10, 814.  | 5.8  | 149       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 57 | Tâ€cell exhaustion in HIV infection. <i>Immunological Reviews</i> , 2019, 292, 149-163.   | 2.8 | 217       |
| 58 | In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients. <i>Aids</i> , 2019, 33, 387-398.   | 1.0 | 8         |
| 59 | Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. <i>Aids</i> , 2019, 33, 1253-1256.   | 1.0 | 20        |
| 60 | Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. <i>Aids</i> , 2019, 33, 185-197.  | 1.0 | 11        |
| 61 | Roles, function and relevance of LAG3 in HIV infection. <i>PLoS Pathogens</i> , 2019, 15, e1007429.   | 2.1 | 27        |
| 62 | PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 1-6.   | 0.9 | 21        |
| 63 | Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2020, 221, 1146-1155.                                | 1.9 | 11        |
| 64 | Advances toward Curing HIV-1 Infection in Tissue Reservoirs. <i>Journal of Virology</i> , 2020, 94, .   | 1.5 | 53        |
| 65 | Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102836.   | 2.0 | 9         |
| 66 | Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion. <i>Journal of Infectious Diseases</i> , 2020, 221, 1135-1145.                                 | 1.9 | 17        |
| 67 | High CD45 expression of CD8+ and CD4+ T cells correlates with the size of HIV-1 reservoir in blood. <i>Scientific Reports</i> , 2020, 10, 20425.  | 1.6 | 8         |
| 68 | Brief Report: Toll-like Receptor 9-1635A/G Polymorphism Is Associated With HIV-1 Rebound After Four Weeks of Interruption of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 252-256. | 0.9 | 3         |
| 69 | A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy. <i>Vaccine</i> , 2020, 38, 4336-4345.  | 1.7 | 3         |
| 70 | Design of a Multiplexed Analyte Biosensor using Digital Barcoded Particles and Impedance Spectroscopy. <i>Scientific Reports</i> , 2020, 10, 6109.  | 1.6 | 12        |
| 71 | Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. <i>Aids</i> , 2020, 34, 681-686.   | 1.0 | 26        |
| 72 | The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?. <i>Frontiers in Immunology</i> , 2020, 11, 1223.  | 2.2 | 18        |
| 73 | HIV-DNA undetectability during chronic HIV infection: frequency and predictive factors. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2994-2997.   | 1.3 | 0         |
| 74 | Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. <i>Frontiers in Microbiology</i> , 2019, 10, 3060.   | 1.5 | 114       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 75 | Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1311-1320. | 1.3 | 15        |
| 76 | Mitochondrial oxidative phosphorylation in peripheral blood mononuclear cells is decreased in chronic HIV and correlates with immune dysregulation. <i>PLoS ONE</i> , 2020, 15, e0231761.                | 1.1 | 18        |
| 77 | HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2258-2263.                           | 1.3 | 7         |
| 78 | HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2020, 94, .  | 1.5 | 28        |
| 79 | A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption. <i>Statistics in Medicine</i> , 2020, 39, 2051-2066.   | 0.8 | 6         |
| 80 | LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 1367-1377.   | 2.5 | 66        |
| 81 | Syndemics and salivary inflammation in people living with HIV/AIDS. <i>Psychology and Health</i> , 2021, 36, 496-510.  | 1.2 | 1         |
| 82 | Biomarkers for the clinical development of antiviral therapies. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 19-32.   | 0.7 | 2         |
| 83 | Predicting Post-treatment HIV Remission: Does Size of the Viral Reservoir Matter?. <i>Frontiers in Microbiology</i> , 2021, 12, 648434.  | 1.5 | 5         |
| 84 | Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. <i>Viruses</i> , 2021, 13, 335.                              | 1.5 | 6         |
| 85 | Unified model of short- and long-term HIV viral rebound for clinical trial planning. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20201015.   | 1.5 | 6         |
| 86 | Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. <i>MBio</i> , 2021, 12, .  | 1.8 | 10        |
| 87 | T cell immune discriminants of HIV reservoir size in a pediatric cohort of perinatally infected individuals. <i>PLoS Pathogens</i> , 2021, 17, e1009533.   | 2.1 | 13        |
| 88 | PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. <i>Cells</i> , 2021, 10, 1152.   | 1.8 | 12        |
| 89 | Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1 infected subjects. <i>Aids</i> , 2021, Publish Ahead of Print, 1549-1559.                                  | 1.0 | 1         |
| 90 | Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 647688.  | 2.2 | 19        |
| 91 | Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium. <i>Journal of Virus Eradication</i> , 2021, 7, 100045.  | 0.3 | 2         |
| 92 | Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. <i>Nature Communications</i> , 2021, 12, 3922.   | 5.8 | 31        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 93  | Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. <i>PLoS Pathogens</i> , 2021, 17, e1009825.  | 2.1 | 17        |
| 94  | Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound. <i>Aids</i> , 2021, 35, 2269-2279.   | 1.0 | 6         |
| 95  | Functionalized gold nanoparticles: promising and efficient diagnostic and therapeutic tools for HIV/AIDS. <i>RSC Medicinal Chemistry</i> , 2020, 11, 1252-1266.  | 1.7 | 26        |
| 98  | Mass cytometry identifies distinct CD4+ T cell clusters distinguishing HIV-1-infected patients according to antiretroviral therapy initiation. <i>JCI Insight</i> , 2019, 4, .   | 2.3 | 15        |
| 99  | Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. <i>JCI Insight</i> , 2020, 5, .   | 2.3 | 53        |
| 100 | Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. <i>PLoS ONE</i> , 2017, 12, e0184929.  | 1.1 | 13        |
| 101 | The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice. <i>PLoS ONE</i> , 2020, 15, e0227715.   | 1.1 | 1         |
| 102 | CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. <i>PLoS Pathogens</i> , 2016, 12, e1005761.  | 2.1 | 350       |
| 103 | Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. <i>PLoS Pathogens</i> , 2016, 12, e1005879.   | 2.1 | 18        |
| 104 | Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. <i>Pathogens and Immunity</i> , 2017, 2, 431.  | 1.4 | 12        |
| 105 | Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8. | 1.4 | 16        |
| 111 | The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. <i>Current HIV Research</i> , 2020, 18, 332-341.  | 0.2 | 9         |
| 112 | Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA. <i>Journal of Virus Eradication</i> , 2016, 2, 124-30.  | 0.3 | 0         |
| 113 | Immune checkpoints and the HIV-1 reservoir: proceed with caution. <i>Journal of Virus Eradication</i> , 2016, 2, 183-6.  | 0.3 | 12        |
| 114 | Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands. <i>Journal of Virus Eradication</i> , 2018, 4, 238-247.   | 0.3 | 3         |
| 115 | Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment. <i>BMJ Open</i> , 2021, 11, e048582.              | 0.8 | 6         |
| 116 | So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research. <i>Viruses</i> , 2022, 14, 135.  | 1.5 | 5         |
| 117 | Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound. <i>Scientific Reports</i> , 2022, 12, 462.   | 1.6 | 6         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 118 | Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring. <i>Statistical Communications in Infectious Diseases</i> , 2022, 14, .    | 0.2 | 0         |
| 119 | Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 833310.   | 2.2 | 10        |
| 120 | Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection. <i>Viruses</i> , 2022, 14, 581.  | 1.5 | 7         |
| 122 | Viral and Host Biomarkers of HIV Remission Post Treatment Interruption. <i>Current HIV/AIDS Reports</i> , 2022, , 1.   | 1.1 | 3         |
| 124 | Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era. <i>Frontiers in Immunology</i> , 2022, 13, .                                 | 2.2 | 1         |
| 125 | Functional Restoration of Exhausted CD8 T Cells in Chronic HIV-1 Infection by Targeting Mitochondrial Dysfunction. <i>Frontiers in Immunology</i> , 0, 13, .   | 2.2 | 9         |
| 126 | Malignancies in HIV. , 2021, , 313-354.  |     | 0         |
| 127 | Towards a molecular profile of antiretroviral therapy-free HIV remission. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 301-307.  | 1.5 | 2         |
| 128 | Elite and posttreatment controllers, two facets of HIV control. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 325-332.  | 1.5 | 3         |
| 129 | Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients. <i>HIV/AIDS - Research and Palliative Care</i> , 0, Volume 14, 365-379.     | 0.4 | 0         |
| 130 | Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells. <i>EBioMedicine</i> , 2022, 84, 104253.  | 2.7 | 8         |
| 131 | Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption. <i>Frontiers in Immunology</i> , 0, 13, .     | 2.2 | 2         |
| 132 | Substantial uneven proliferation of CD4+ T cells during recovery from acute HIV infection is sufficient to explain the observed expanded clones in the HIV reservoir. <i>Journal of Virus Eradication</i> , 2022, 8, 100091. | 0.3 | 2         |
| 133 | HLA-B*57 and B*58 associate with predictors of reservoir size in an acutely treated HIV cohort. <i>AIDS Research and Human Retroviruses</i> , 0, , .   | 0.5 | 0         |
| 134 | Slow progression of pediatric HIV associates with early CD8+ T cell PD-1 expression and a stem-like phenotype. <i>JCI Insight</i> , 2023, 8, .   | 2.3 | 2         |
| 136 | Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFN $\gamma$ Responses of HIV-Infected Persons on Antiretroviral Therapy. <i>Vaccines</i> , 2023, 11, 211.  | 2.1 | 0         |
| 137 | Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes. <i>EBioMedicine</i> , 2023, 91, 104549.                           | 2.7 | 3         |